Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

Cantargia AB
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cantargia AB
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cantargia AB
STO:CANTA
Revenue
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Revenue
kr1.3B
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Revenue
kr814.5m
CAGR 3-Years
58%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Revenue
kr3.6B
CAGR 3-Years
32%
CAGR 5-Years
21%
CAGR 10-Years
22%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Revenue
kr25.4B
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
26%
BioArctic AB
STO:BIOA B
Revenue
kr616m
CAGR 3-Years
115%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Cantargia AB
Glance View

Market Cap
332.8m SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
1.024 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Cantargia AB's Revenue?
Revenue
0 SEK

Based on the financial report for Sep 30, 2024, Cantargia AB's Revenue amounts to 0 SEK.

Back to Top